Medicine & Life Sciences

1. Non-Hodgkin's Lymphoma 100%
2. Multiple Myeloma 83%
3. Lymphoma, Large B-Cell, Diffuse 69%
4. Rituximab 64%
5. ibritumomab tiuxetan 60%
6. Lymphoma 58%
7. B-Cell Lymphoma 55%
8. Survival 51%
9. Radioimmunotherapy 47%
10. Follicular Lymphoma 42%
11. Plasma Cells 42%
12. Waldenstrom Macroglobulinemia 41%
13. Lenalidomide 40%
14. B-Cell Chronic Lymphocytic Leukemia 38%
15. Mantle-Cell Lymphoma 37%
16. Progression-Free Survival 34%
17. B-Lymphocytes 32%
18. Immunoglobulin Light-chain Amyloidosis 30%
19. Therapeutics 30%
20. Neoplasms 23%
21. Bone Marrow 23%
22. Dexamethasone 21%
23. Thalidomide 20%
24. Hodgkin Disease 19%
25. Stem Cell Transplantation 18%
26. Recurrence 15%
27. Clinical Trials 14%
28. Everolimus 14%
29. Blood Cells 14%
30. Cyclophosphamide 14%
31. Drug Therapy 14%
32. Smoldering Multiple Myeloma 13%
33. T-Lymphocytes 12%
34. Serum 11%
35. Bortezomib 11%
36. Confidence Intervals 11%
37. Monoclonal Gammopathy of Undetermined Significance 11%
38. Prednisone 11%
39. T-Cell Lymphoma 11%
40. Peripheral T-Cell Lymphoma 10%
41. temsirolimus 10%
42. Stem Cells 10%
43. PCI 32765 9%
44. Amyloidosis 9%
45. Cladribine 9%
46. Cytokines 9%
47. Light 9%
48. Vincristine 9%
49. Monocytes 9%
50. Lymphocyte Count 9%